Descrição
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma
ESMO 2022: Adjuvant Nivolumab Plus Ipilimumab vs Placebo for Localized Renal Cell Carcinoma at High Risk of Relapse After Nephrectomy: Results From the Randomized, Phase 3 CheckMate 914 Trial
Toni Choueiri, MD on X: Masterful presentation by @motzermd reporting subgroup analyses from #CheckMate914 (part A). Exploratory analyses suggest tumor PD-L1 expression influenced outcome of adjuvant IPI+NIVO in pts with localized #RCC
CheckMate-914 trial's disappointing results cast doubt on BMS's plans to advance PD-1 inhibitors
Adjuvant Therapy for Renal Cell Carcinoma: End Points, Outcomes, and Risk Assessments
Adjuvant Nivolumab/Ipilimumab vs Placebo in Localized Renal Cell Carcinoma - The ASCO Post
Adjuvant immunotherapy does not improve DFS in renal cancer
Strengthening Our Grip on Immuno-Oncology in Genitourinary Cancers: Understanding Science Through Stories
Adjuvant Therapy Options in Renal Cell Carcinoma: Where Do We Stand?
CheckMate 914: Nivolumabe adjuvante mais ipilimumabe no tratamento do carcinoma de células renais localizado com alto risco de recidiva - Oncologia Brasil
Adjuvant immunotherapy does not improve DFS in renal cancer
Ongoing Trials Testing IO in the Adjuvant Setting
Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial
Prevalence, Disease-free, and Overall Survival of Contemporary Patients With Renal Cell Carcinoma Eligible for Adjuvant Checkpoint Inhibitor Trials - ScienceDirect
The 2022 Updated European Association of Urology Guidelines on the Use of Adjuvant Immune Checkpoint Inhibitor Therapy for Renal Cell Carcinoma - European Urology
de
por adulto (o preço varia de acordo com o tamanho do grupo)
